Medication-info.com Search Menu

Ipratropium Nasal (Atrovent): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
21 mcg
Brand names:
Drug class:
Active ingredient:

Patient information: uses, side effects, how to take - Ipratropium Nasal

INSTRUCTIONS FOR USE

Ipratropium Bromide

Nasal Solution 0.03%

(Nasal Spray) 21 mcg/spray

Read complete instructions carefully before using.

In order to ensure proper dosing, do not attempt to change the size of the spray opening.

Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. Read complete instructions carefully and use only as directed.

To Use:

  1. 1. Remove the plastic dust cap and the safety clip from the nasal spray pump (Figure 1).

The safety clip prevents the accidental discharge of the spray in your pocket or purse.

  1. 2. The nasal spray pump must be primed before Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) is used for the first time. To prime the pump, hold the bottle with your thumb at the base and your index and middle fingers on the white shoulder area. Make sure the bottle points upright and away from your eyes. Press your thumb firmly and quickly against the bottle seven (7) times (Figure 2).

The pump is now primed and can be used. Your pump should not have to be reprimed unless you have not used the medication for more than 24 hours; repriming the pump will only require two sprays. If you have not used your nasal spray for more than seven (7) days, repriming the pump will require seven sprays.

3. Before using Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray), blow your nose gently to clear your nostrils if necessary.

  1. 4. Close one nostril by gently placing your finger against the side of your nose, tilt your head slightly forward and, keeping the bottle upright, insert the nasal tip into the other nostril (Figure 3). Point the tip toward the back and outer side of the nose.
  1. 5. Press firmly and quickly upwards with the thumb at the base while holding the white shoulder portion of the pump between your index and middle fingers. Following each spray, sniff deeply and breathe out through your mouth.
  2. 6. After spraying the nostril and removing the unit, tilt your head backwards for a few seconds to let the spray spread over the back of the nose.
  3. 7. Repeat steps 4 through 6 in the same nostril.
  4. 8. Repeat steps 4 through 7 in the other nostril (i.e., two sprays per nostril).
  5. 9. Replace the plastic dust cap and safety clip.
  6. 10. At some time before the medication is completely used up, you should consult your physician or pharmacist to determine whether a refill is needed. You should not take extra doses or stop using Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) without consulting your physician.

To Clean:

If the nasal tip becomes clogged, remove the plastic dust cap and safety clip. Hold the nasal tip under running, warm tap water (Figure 4) for about a minute. Dry the nasal tip, reprime the nasal spray pump (step 2 above), and replace the plastic dust cap and safety clip.

Caution:

Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) is intended to relieve your rhinorrhea (runny nose) with regular use. It is therefore important that you use Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) as prescribed by your physician. For most patients, some improvement in runny nose is usually apparent during the first full day of treatment with Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray). Some patients may require up to two weeks of treatment to obtain maximum benefit.

Do not spray Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray) in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. Should acute eye pain or blurred vision occur, contact your doctor.

Should you experience excessive nasal dryness or episodes of nasal bleeding, contact your doctor.

If you have glaucoma or difficulty urinating due to an enlargement of the prostate, be sure to tell your physician prior to using Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray).

If you are pregnant or you are breast feeding your baby, be sure to tell your physician prior to using Ipratropium Bromide Nasal Solution 0.03% (Nasal Spray).

STORAGE: Store at 68° to 77°F (20° to 25°C); excursions are permitted to 59° to 86°F (15° to 30°C). Avoid freezing. Keep out of reach of children.

Do not spray in the eyes.

Distributed by:

Oceanside Pharmaceuticals, a division of

Bausch Health US, LLC

Bridgewater, NJ 08807 USA

Manufactured by:

Bausch Health Companies Inc.

Laval, Quebec H7L 4A8, Canada

© 2025 Bausch Health Companies Inc. or its affiliates

Revised: May 2025

90005900 (Folded)

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: ANDA 076025 · View the label on DailyMed

Revision date stated in the text: May 2025

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Ipratropium Nasal

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Anticholinergic
Active ingredient Ipratropium bromide 21 mcg
Dosage form Spray, metered
Route Nasal
Marketing status listed in the FDA NDC Directory
Company (applicant) BAUSCH
FDA approval ANDA 076025Abbreviated New Drug Application (ANDA) – generic drug Approved March 31, 2003
Therapeutic equivalence (TE) code ABCodes starting with A mean the FDA rates the drug therapeutically equivalent to its reference drug (Orange Book).
Manufacturers 8 labelers list this drug on DailyMed
Packages (NDC)
Package
21 mcg – 345 in 1 bottle, spray / 1 in 1 carton NDC 68682-398-30

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.